ToxStrategies LLC, a BlueRidge Life Sciences (BRLS) company, is pleased to announce that Ming Kung, PhD, DABT, has joined the company as President, effective May 18, 2026. Most recently a Principal, Regulatory Sciences, at ExxonMobil Biomedical Sciences, Dr. Kung brings deep expertise in toxicology, risk assessment, computational toxicology, and product stewardship. His extensive experience includes leading organizations that operate at the intersection of science and regulation.
“I’m excited to have the opportunity to continue to build on ToxStrategies’ strong track record, expand how we serve our clients, and position the firm for continued growth and success,” said Dr. Kung.
As a part of this transition, ToxStrategies co-founder and current President Laurie Haws, PhD, DABT, ATS, will assume the role of Strategic Advisor for BRLS, where she will work closely with its CEO and Executive Leadership team on strategic priorities across the organization. We are grateful for Laurie’s exceptional leadership, vision, lasting, and continuing contributions to ToxStrategies.
We are thrilled to welcome Dr. Kung to the BRLS family and look forward to ToxStrategies’ next chapter under his guidance.
